Post-Hemorrhagic Anemia Treatment Market Trends

  • Report ID: 3784
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Post-Hemorrhagic Anemia Treatment Market Trends

Growth Drivers

  • Rising Cases of Blood Disorders– Hemophilia is a genetic blood condition that hinders the healthy clotting and coagulation of blood. Therefore, patients require frequent blood transfusion as a part of their treatment. Moreover, in the United States, around 18,400 people were diagnosed with hemophilia in the year 2021. Furthermore, around 10,000 people are suffering with other bleeding disorders.
  • Rising Incidents of Accidents– Accidents can cause severe injuries and lead to heavy blood loss; therefore, timely control of blood loss is an absolute necessity. According to the World Health Organization, every year around 1.3 million people die de to vehicle crash and in other road accidents. Moreover, over 50% of deaths on road is attributed to pedestrian, cyclists, and motorcyclists. In addition to this, road accidents are the primary cause of death for people between the age 5 to 29 years.
  • Rise in the Number of Surgical Procedures  – Surgery involves massive blood loss that is likely to boost the demand for post-hemorrhagic anemia treatment. Around 40 to 50 million major procedures are performed annually in the USA, and about 20 million in Europe, for a startling total of nearly 310 million worldwide.
  • Rising Cases of Heart Patient– Heart patients are usually prescribed blood thinning medicines that increases the chances of post-hemorrhagic anemia. In the world, around 550 million people suffer from heart issues and circulation disorders. These problems are usually caused by unhealthy lifestyle & eating habits, and ageing population. Moreover, nearly 60 million people all over the world develops the heart disease, each year. This count is almost equal to entire population of the United Kingdom.
  • A Family History of Anemia – A person with anemia is already in deficiency of red blood cells and it can even worsen the situation in the case of post-hemorrhagic anemia. Therefore, post hemorrhagic anemia treatment can be used in aplastic anemia treatment, sickle-cell anemia treatment, and others. According to World Health Organization statistics, anemia affects 40% of pregnant women and 42% of children under the age of five worldwide.

Challenges

  • Shortage of skilled workers – A patient suffering from post-hemorrhagic anemia can die if not handled under the immediate expert professionals. Therefore, lack of skilled workers is expected to hamper the market growth.
  • A lack of some medical therapies' accessibility
  • Lack of treatment awareness in certain under-developed regions

Post-Hemorrhagic Anemia Treatment Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

5.9%

Base Year Market Size (2023)

USD 5.3 Billion

Forecast Year Market Size (2036)

USD 11.16 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3784
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of post-hemorrhagic anemia treatment is evaluated at USD 5.58 Billion.

The post-hemorrhagic anemia treatment market size was valued at USD 5.3 Billion in 2023 and is anticipated to exceed USD 11.16 Billion by the end of 2036, registering over 5.9% CAGR during the forecast period i.e., between 2024-2036. Growing number of trauma cases across the globe, and increasing prevalence of bleeding disorders. are the major factors driving the market growth.

North America is poised to dominate majority industry share by 2036, attributed to high number of hospital admissions, and rising government focus to improve healthcare infrastructure in the region.

Rockwell Medical, Inc., Amgen Inc., Vifor Pharma Management Ltd., F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., AMAG Pharmaceuticals, Akebia Therapeutics
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample